<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, June 9, 2020 (HealthDay News) — Percutaneous cryoablation (PCA) for stage I renal cell carcinoma (RCC) results in good outcomes, with a 10-year disease-specific survival of 94 percent, according to a study published online June 9 in Radiology<\/i>.<\/p>\n
John Morkos, from Johns Hopkins University in Baltimore, and colleagues examined the 10-year oncologic outcomes of PCA for stage I RCC. Ten-year overall survival, recurrence-free survival, and disease-free survival were calculated for 134 patients with biopsy-proven RCC who underwent PCA. Results were compared to those of matched partial nephrectomy (PN) and radical nephrectomy (RN) cohorts from the National Cancer Database.<\/p>\n
The researchers found that at five and 10 years, respectively, overall survival was 86 and 72 percent, recurrence-free survival was 85 and 69 percent (improved over surgery), and disease-specific survival was 94 and 94 percent (similar to surgery). There was a 2.3 percent 10-year risk for hemodialysis, while the risk for metachronous RCC was 6 percent. Decreasing overall survival was seen with increasing comorbidity index in a Charlson\/Deyo Combined Comorbidity score analysis. In all Charlson\/Deyo Combined Comorbidity score categories, the PCA cohort outperformed both RN- and PN-matched subgroups.<\/p>\n
“For certain patients, cryoablation is equivalent to surgery with fewer side effects,” a coauthor said in a statement. “The risk of significant complications from this procedure is about 6 percent, compared to between 15 and 20 percent for surgery. In addition, recovery is much faster than with surgery.”<\/p>\n
One author disclosed financial ties to the biotechnology industry.<\/p>\n